Navana Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 1/6
Navana Pharmaceuticals has a total shareholder equity of BDT4.5B and total debt of BDT4.8B, which brings its debt-to-equity ratio to 105.9%. Its total assets and total liabilities are BDT10.4B and BDT5.9B respectively. Navana Pharmaceuticals's EBIT is BDT865.7M making its interest coverage ratio 3. It has cash and short-term investments of BDT328.9M.
Anahtar bilgiler
105.9%
Borç/özkaynak oranı
৳4.79b
Borç
| Faiz karşılama oranı | 3x |
| Nakit | ৳328.92m |
| Eşitlik | ৳4.52b |
| Toplam yükümlülükler | ৳5.85b |
| Toplam varlıklar | ৳10.38b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: NAVANAPHAR's short term assets (BDT5.2B) do not cover its short term liabilities (BDT5.4B).
Uzun Vadeli Yükümlülükler: NAVANAPHAR's short term assets (BDT5.2B) exceed its long term liabilities (BDT410.9M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: NAVANAPHAR's net debt to equity ratio (98.6%) is considered high.
Borcun Azaltılması: Insufficient data to determine if NAVANAPHAR's debt to equity ratio has reduced over the past 5 years.
Borç Kapsamı: NAVANAPHAR's debt is not well covered by operating cash flow (1.9%).
Faiz Kapsamı: NAVANAPHAR's interest payments on its debt are not well covered by EBIT (3x coverage).